The Trusted Source For Health
5 supervisors at a city bus sightseeing company declare they were wrongfully fired for legal and medical cannabis use, new court papers present. The workforce, all field supervisors at Topview Sight Seeing, say they were being just about every canned on Feb. 17 past year …
Nearly a month after the abrupt closure of three Anytime Fitness locations in Lincoln, a South Dakota company has purchased two of the gyms and hopes to have them reopened by Feb. 1. Blue Star Investments, based in Sioux Falls, purchased the locations — one …
Company Overview
From
own and licensed technologies worldwide for transmucosal and transdermal
delivery of legal medical or recreational cannabis (other than in the field of
oral care) and cannabinoids (“CBD”). While part of the cannabis family, CBD,
which contains less than 0.3{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} tetrahydrocannabinol (“THC”), the psychoactive
compound that produces the “high” in marijuana, is distinguished from cannabis
by its use, physical appearance and lower THC concentration (cannabis generally
has a THC level of 10{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} or more). The Company’s initial product was an oral
transmucosal patch platform which provides for loaded actives to be absorbed by
the buccal mucosa into the body. Although the Company was able to launch the
product and received some limited initial orders,
ultimately elected to pursue other opportunities which they believed offered the
Company greater potential for growth and ultimate profitability.
Accordingly, on
with
license of SZS’s novel cannabinoid therapeutic focused on treatment of autism,
schizophrenia, Parkinson’s disease, Alzheimer’s disease and other
neuropsychiatric disorders.
of the largest multidisciplinary research hospitals in
and over 850,000 patient visits a year.
Development
in medical journals in addition to almost 160 clinical trials.
Accompanying the license agreement is a joint research and development
agreement, which will focus on continuing the clinical program spearheaded by
Dr.
cannabinoid therapy.
and pediatric neurology and was the principal investigator of the first ever
cannabis research study conducted on autistic children.
based medical cannabis as an adjuvant therapy for refractory behavioral problems
in children with ASD. The results provided very compelling evidence that medical
cannabis is an effective therapy for children on the autism spectrum. Conditions
in 80{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} of the children improved, with 62{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} of parents reporting substantial
improvements. Half of the children had improved communication and 40{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} reported a
decrease in anxiety. The same children had not shown improvement with
conventional drug therapies.
combination therapy that is believed to be significantly more effective than the
cannabis-only formulation that had been used in the aforementioned study. The
Company plans to further develop this therapeutic and conduct clinical studies
to further substantiate its safety and efficacy beginning in neuropsychiatric
disorders.
The clinical studies of the therapeutic are expected to require an investment of
up to
The Company’s current business plan is to (i) conduct clinical studies on and
commercialize the cannabinoid-based therapeutic and (ii) concentrate on cannabis
related investment and development opportunities through direct equity
investments, joint ventures, licensing agreements or acquisitions.
On
submitted a clinical trial application to the
approval of a Phase II clinical trial to study the safety and efficacy of its
neuroprotective cannabinoid therapeutic to treat autism related spectrum
disorders (ASD) and other neuropsychiatric illnesses.
4 Results of operations
Three months ended
The Company had no revenue during the three months ended
2021.
Our operating expenses for the three months ended
include officers’ compensation and professional fees. The decrease from the 2021
quarter to the 2022 quarter was primarily a result of a reduction of other
operating expenses in the amount of
Other income and (expenses) was
30, 2022
conversion of notes payable increased by
discounts decreased by
Our net loss for the three months ended
compared to the net loss of
Nine months ended
30, 2021
The Company had no revenue during the nine months ended
compared to revenue from sales of its oral transmucosal patch platform of
incurred gross profit (loss) of
Company shifted its focus from that product in the second half of 2021.
Our operating expenses for the nine months ended
include officers’ compensation and professional fees. The decrease from the 2021
period to the 2022 period was primarily a result of a reduction of
officers compensation and decreased other operating expenses of
Other income and (expenses) was
30, 2022
liability income decreased by
accrued interest to common stock decreased by
discounts decreased by
Our net loss for the nine months ended
compared to the net loss of
Liquidity and Capital Resources
We had
2021
At
to third parties compared to
The proceeds from loans and convertible debentures as well as cash on hand is
being used to fund the operations of our current operations.
The following table provides detailed information about our net cash flows for
the nine months ended
September 30 , September 30,
2022 2021
Net cash used in operating activities
Net cash used in investing activities
- - Net cash provided by financing activities - 500,000 Net increase (decrease) in cash$ (88,426 ) $ 343,405
Critical Accounting Policies and Estimates
The
Disclosure About Critical Accounting Policies” suggesting that companies provide
additional disclosure and commentary on their most critical accounting policies.
In Financial Reporting Release No. 60, the
accounting policies as the ones that are most important to the portrayal of a
company’s financial condition and operating results and require management to
make its most difficult and subjective judgments, often as a result of the need
to make estimates of matters that are inherently uncertain. Based on this
definition, we have identified the following significant policies as critical to
the understanding of our financial statements. The preparation of financial
statements in conformity with generally accepted accounting principles requires
management to make a variety of estimates and assumptions that affect (i) the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities as of the date of the financial statements and (ii) the reported
amounts of revenues and expenses during the reporting periods covered by the
financial statements. Our management expects to make judgments and estimates
about the effect of matters that are inherently uncertain. As the number of
variables and assumptions affecting the future resolution of the uncertainties
increase, these judgments become even more subjective and complex. Although we
believe that our estimates and assumptions are reasonable, actual results may
differ significantly from these estimates. Changes in estimates and assumptions
based upon actual results may have a material impact on our results.
5
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.
© Edgar Online, source
Cannaray Minimal, a main European healthcare hashish and wellness CBD company, is right now saying the signing of an special LOI for the listing of its CBD division (Cannaray Manufacturers Ltd and Love CBD Wellness Ltd) through a reverse takeover of Cellular Items PLC (LSE: …
On July 5, 2022, Bayhealth Healthcare Heart, Inc. posted see of a data breach that affected the delicate data of as numerous as 17,481 clients. In its detect, Bayhealth stated that the incident included a breach at a single of the company’s distributors utilised to …
ATHENS – A Germany pharmaceutical development and production corporation will grow its Animal Overall health World Innovation heart in Athens.
Governor Brian P. Kemp announced that Boehringer Ingelheim, a worldwide analysis-pushed pharmaceutical advancement and production organization centered in Germany, will broaden its Animal Wellness Global Innovation heart in Athens, Ga. The $57 million investment decision will maximize laboratory house and deliver extra analysis and progress capabilities and functions, which include 55 new positions, to the website, Hot News Today.
“Boehringer Ingelheim has been a superb member of our Ga Everyday living Sciences group, and we are so psyched to see them keep on to decide on Georgia to expand,” said Governor Kemp. “Georgia’s university technique gives the expertise lifetime science firms want, and our pro-enterprise natural environment combined with our commitment to innovation proceeds to develop alternatives for hardworking Georgians across the state.”
As a entire world-foremost, research-driven pharmaceutical firm, Boehringer Ingelheim focuses on three business locations: Human Pharma, Animal Overall health, and Biopharmaceutical Deal Producing. The firm manufactures nicely-respected and widely used vaccines, parasite-control goods, and therapeutics for pets, horses, and livestock.
“Our new and expanded space has been exclusively built to motivate nearer connections among teams and colleagues. Immediately after functioning in a distanced or virtual way for so numerous months, we all have a considerably better appreciation for the power of the two formal and spontaneous collaboration,” explained Caroline Belmont, US Head of World wide Innovation. “The significant expense in increasing and maximizing our Athens International Innovation website will deliver not only a cozy and flexible physical house that inspires collaboration, but also will bring several new tools and systems to spark the innovation that will eventually assistance make improvements to animal and human wellbeing, Hot News Today.”
Building commenced a short while ago on a new 63,000-square-foot facility, situated at 1730 Olympic Drive in Athens, that will join two present structures at the moment housing laboratory and administrative house, along with a 5,000-square-foot growth and partial renovation of current World-wide Innovation facilities in Athens. The new facility is slated to be full in spring 2024. When complete, the growth will deliver Boehringer Ingelheim’s International Innovation footprint in Athens to just about 115,000 sq. feet and accommodate an additional 55 exploration and advancement positions at the website. Go to the company’s U.S. Occupations web site to master about investigation and enhancement prospects at Boehringer Ingelheim’s Animal Health and fitness small business and its Athens, Ga, web-site.
Sustainability has been deemed through the style and design method and numerous sustainable characteristics will be included in the new Global Innovation facility. The new making and enlargement will characteristic substantial use of pure light in workplaces, laboratories, and collaboration spaces, with flooring to ceiling windows in quite a few spots. Building particles will be segregated to facilitate recycling or disposal as correct, Hot News Today.
“Boehringer Ingelheim’s growth in Athens-Clarke County demonstrates their ongoing motivation to innovation, engagement, and expertise advancement in our local community that displays the company’s world management in animal and human health,” said Mayor Kelly Girtz. “Boehringer Ingelheim recognizes the toughness of Athens-Clarke County as a bioscience and exploration hub with lively high quality of lifestyle, and we look ahead to our continued collaboration.”
Considering that 2018, Boehringer Ingelheim has invested a lot more than $100 million in its Georgia amenities and grown its work in the state by a lot more than 200, which include its vaccine-manufacturing and investigate website in Athens, its US headquarters business office in Duluth, and its poultry vaccine-production web site in Gainesville. The enterprise employs additional than 1,200 folks in Georgia between the web pages. Boehringer Ingelheim’s Animal Health and fitness small business has deep roots in the U.S. From a commence in St. Joseph, Missouri, more than 100 yrs in the past, it has developed to encompass 7 websites, together with the a few in Ga.
Director of Lifestyle Sciences EJane Caraway represented the Ga Department of Financial Development’s (GDEcD) World-wide Commerce team on this aggressive undertaking in partnership with the Athens-Clarke County Financial Advancement Office and Georgia Energy.
“Through the effective growth and addition of firms like Boehringer Ingelheim, Georgia proceeds to create by itself as a increasing hub for investigate and innovation within the daily life sciences business,” said GDEcD Commissioner Pat Wilson. “Boehringer Ingelheim has lengthy been an significant portion of our lifestyle sciences community in Georgia, leveraging impressive connections and resources throughout the College Process of Georgia to conduct cutting-edge exploration into the avoidance and treatment of animal illnesses. It is normally interesting to rejoice progress inside of an vital present market, but even more gratifying when the work staying accomplished in Georgia could perhaps have such a significantly reaching affect.”
There are far more than 2,200 clinical trials recruiting or underway in Georgia. From 2014 as a result of 2017, there were 547 patents awarded to applicants from Ga for medicine and prescribed drugs. In 2021, Georgia exported $3.2 billion in immunological solutions and $1.9 billion in professional medical gadgets and prescribed drugs.
About Boehringer Ingelheim
Boehringer Ingelheim Animal Overall health is doing the job on first-in-class innovation for the prediction, avoidance, and therapy of disorders in animals. For veterinarians, pet homeowners, producers, and governments in extra than 150 international locations, the firm offers a significant and impressive portfolio of solutions and services to boost the overall health and properly-becoming of companion animals and livestock. Learn far more about Boehringer Ingelheim Animal Health and fitness Usa at bi-animalhealth.com.